GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genor Biopharma Holdings Ltd (HKSE:06998) » Definitions » Retained Earnings

Genor Biopharma Holdings (HKSE:06998) Retained Earnings : HK$-7,445.4 Mil (As of Jun. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Genor Biopharma Holdings Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Genor Biopharma Holdings's retained earnings for the quarter that ended in Jun. 2024 was HK$-7,445.4 Mil.

Genor Biopharma Holdings's quarterly retained earnings declined from Jun. 2023 (HK$-6,989.8 Mil) to Dec. 2023 (HK$-7,427.1 Mil) and declined from Dec. 2023 (HK$-7,427.1 Mil) to Jun. 2024 (HK$-7,445.4 Mil).

Genor Biopharma Holdings's annual retained earnings declined from Dec. 2021 (HK$-6,594.7 Mil) to Dec. 2022 (HK$-6,829.8 Mil) and declined from Dec. 2022 (HK$-6,829.8 Mil) to Dec. 2023 (HK$-7,427.1 Mil).


Genor Biopharma Holdings Retained Earnings Historical Data

The historical data trend for Genor Biopharma Holdings's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genor Biopharma Holdings Retained Earnings Chart

Genor Biopharma Holdings Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Retained Earnings
Get a 7-Day Free Trial -5,358.79 -6,594.69 -6,829.80 -7,427.13 -7,304.61

Genor Biopharma Holdings Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6,829.80 -6,989.83 -7,427.13 -7,445.41 -7,304.61

Genor Biopharma Holdings Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


Genor Biopharma Holdings  (HKSE:06998) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Genor Biopharma Holdings Business Description

Traded in Other Exchanges
Address
690 Bibo Road, Room 401-17, Building 6, Pudong New District, Shanghai, CHN, 201203
Genor Biopharma Holdings Ltd is a commercial-ready biopharmaceutical company focusing on developing and commercializing oncology and autoimmune drugs. The company is focused on therapeutic areas with substantial unmet medical needs in oncology, autoimmune, and other chronic diseases. Its key drug candidates include GB491 (lerociclib), a differentiated oral CDK4/6 inhibitor; GB221, a novel HER2 mAb drug candidate; geptanolimab (GB226), GB492, a STING agonist expected to exert synergistic effects in combination with GB226; GB242, an infliximab (Remicade) biosimilar; and GB223, a RANKL, and others.
Executives
Forebright New Opportunities Fund, L.p. 2101 Beneficial owner
Forbright Global Limited 2201 Interest of corporation controlled by you
Fnof Gp Limited 2201 Interest of corporation controlled by you
Deg – Deutsche Investitions- Und Entwicklungsgesellschaft Mbh 2101 Beneficial owner
Hsg Growth V Holdco Q, Ltd. 2101 Beneficial owner
Hsg Holding Limited 2201 Interest of corporation controlled by you
Snp China Enterprises Limited 2201 Interest of corporation controlled by you
Hongshan Capital Growth Fund Management I, L.p. 2201 Interest of corporation controlled by you
Shen Nan Peng 2201 Interest of corporation controlled by you
Hongshan Capital Growth Fund I, L.p. 2101 Beneficial owner
Hongshan Capital Growth Fund V, L.p. 2201 Interest of corporation controlled by you
Hsg Growth V Management, L.p. 2201 Interest of corporation controlled by you
Hongshan Capital Management I, L.p. 2201 Interest of corporation controlled by you
Hongshan Capital I, L.p. 2101 Beneficial owner
Ni Xin 2101 Beneficial owner

Genor Biopharma Holdings Headlines

No Headlines